This trial is for a new treatment for CMV in newborns. It is a safety trial to see if the new treatment is safe and effective.
2 Primary · 0 Secondary · Reporting Duration: 12 weeks
Active Control
Experimental Treatment
23 Total Participants · 3 Treatment Groups
Primary Treatment: Cohort 2 Antiviral medication + CMV CTLs · No Placebo Group · Phase 2
Age No minimum age - 21 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: